These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 7192148)

  • 1. [Study of visually evoked potentials in schizophrenic patients treated with sulpiride].
    Brosteanu ER; Floru L
    Arzneimittelforschung; 1980; 30(8):1306-9. PubMed ID: 7192148
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The behaviour of visually evoked potentials (VEP) in schizophrenia under gradually rising doses of fluphenazine dihydrochloride (author's transl)].
    Brosteanu ER; Floru L
    Arzneimittelforschung; 1977; 27(6):1231-3. PubMed ID: 578448
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Study of the clinical effects of sulpiride and perphenazine in 82 schizophrenic patients by the double blind method].
    Asada S; Ishimaru T; Kubo S; Kodama H; Masuda K
    Encephale; 1976; 2(1):73-83. PubMed ID: 770152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulpiride: evaluation of antipsychotic activity in schizophrenic patients.
    Mielke DH; Gallant DM; Roniger JJ; Kessler C; Kessler LR
    Dis Nerv Syst; 1977 Jul; 38(7):569-71. PubMed ID: 326504
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Distribution of latencies of visual evoked potentials in a sample of schizophrenic patients].
    Małyszczak K; Kubiszewski M; Pilecki W; Maciejowski A; Sobieszczańska M
    Psychiatr Pol; 2003; 37(6):989-97. PubMed ID: 14727371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosage finding and outcome in the treatment of schizophrenic inpatients with amisulpride. Results of a drug utilization observation study.
    Linden M; Scheel T; Xaver Eich F
    Hum Psychopharmacol; 2004 Mar; 19(2):111-9. PubMed ID: 14994321
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [ERPs changes during neuroleptic treatment in schizophrenia--a vulnerability marker in schizophrenia].
    Asato N; Hirayasu Y; Hiramatsu K; Ohta H
    Seishin Shinkeigaku Zasshi; 1999; 101(3):254-76. PubMed ID: 10375977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of treatment of schizophrenic and schizoaffective patients with sulpiride (Eglonyl Alkaloid) in comparison with perphenazine (Perfenazin Spofa)].
    Svestka J; Rysánek R; Náhunek K; Cesková E
    Cesk Psychiatr; 1990 Jun; 86(3):145-56. PubMed ID: 2225184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical-neuroleptic investigation of N-((1-ethyl-pyrrolidine-2-yl)-methyl)-2-methoxy-5-sulfamyl-benzamide-neuroleptic sulpiride (Dogmatil) in acutly ill schizophrenics].
    Haase HJ; Floru L; Ulrich F
    Int Pharmacopsychiatry; 1974; 9(2):77-94. PubMed ID: 4603413
    [No Abstract]   [Full Text] [Related]  

  • 10. [Brain evoked potentials in patients with Alzheimer's disease and schizophrenia: a comparative study].
    Chen X; Zhang M; Wang J
    Zhonghua Yi Xue Za Zhi; 1998 Sep; 78(9):674-6. PubMed ID: 11038791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Visual evoked potentials in idiopathic intracranial hypertension.
    Kesler A; Vakhapova V; Korczyn AD; Drory VE
    Clin Neurol Neurosurg; 2009 Jun; 111(5):433-6. PubMed ID: 19345474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intercentral interactions during typical and atypical neuroleptics administration].
    Kachalova LM; Popova NS
    Biull Eksp Biol Med; 1999 May; 127(5):512-5. PubMed ID: 10399568
    [No Abstract]   [Full Text] [Related]  

  • 13. Abnormalities of auditory event-related potentials in schizophrenia prior to treatment.
    Hirayasu Y; Asato N; Ohta H; Hokama H; Arakaki H; Ogura C
    Biol Psychiatry; 1998 Feb; 43(4):244-53. PubMed ID: 9513733
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The P 300 potential in schizophrenia].
    Laurent A; Garcia-Larrea L; Dalery J; Terra JL; D'Amato T; Marie-Cardine M; Mauguière F
    Encephale; 1993; 19(3):221-7. PubMed ID: 8275907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Sulpiride: a neuroleptic agent of new generation with unique pharmacological qualities and rather wide range of clinical applications].
    Pawłowski L
    Psychiatr Pol; 1993; 27(2):199-205. PubMed ID: 8104350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sulpiride: evaluation of antipsychotic activity in chronic schizophrenic patients.
    Mielke DH; Gallant DM; Roniger JJ; Kessler C
    Psychopharmacol Bull; 1977 Jul; 13(3):40-1. PubMed ID: 18758
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of ongoing alpha rhythm on the visual evoked potential.
    Becker R; Ritter P; Villringer A
    Neuroimage; 2008 Jan; 39(2):707-16. PubMed ID: 17977023
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Transient and steady-state electroretinograms and visual evoked potentials to pattern and uniform-field stimulation in humans].
    Nakayama M
    Fukuoka Igaku Zasshi; 1994 Jul; 85(7):225-34. PubMed ID: 8070753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of lipoic acid on lipid peroxidation and visual evoked potentials (VEPs) in rats exposed to chronic restraint stress.
    Akpinar D; Yargiçoğlu P; Derin N; Alicigüzel Y; Sahin M; Ağar A
    Int J Neurosci; 2007 Dec; 117(12):1691-706. PubMed ID: 17987471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factor structure of the human gamma band oscillatory response to visual (contrast) stimulation.
    Carozzo S; De Carli F; Beelke M; Saturno M; Garbarino S; Martello C; Sannita WG
    Clin Neurophysiol; 2004 Jul; 115(7):1669-76. PubMed ID: 15203068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.